T 0250/16 (Adjuvanted priming influenza vaccine/SEQIRUS) of 21.09.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T025016.20210921
- Date of decision
- 21 September 2021
- Case number
- T 0250/16
- Online on
- 22 December 2021
- Petition for review of
- -
- Application number
- 08854338.4
- IPC class
- A61K 39/145
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Vaccination with multiple clades of H5 influenza A virus
- Applicant name
- Seqirus UK Limited
- Opponent name
- GlaxoSmithKline Biologicals SA
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 54European Patent Convention Art 56Rules of procedure of the Boards of Appeal Art 13
- Keywords
- Main request - novelty (yes), inventive step (yes)
Late-filed argument - admitted (no) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent with claims 1 to 4 of the main request, filed as auxiliary request 23 with the letter dated 2 January 2017, and a description to be adapted thereto.